Company

• Mission
• About Us
• Genus Overview
• Management
• Board of Directors
• Scientific Advisory Board
• Clinical and Research Partners
• Contact
• Sitemap

Why Target MUC1-C?

Clinical Trials

• Summary
• GO-203
• Phase 2 AML Clinical Trial

The Science

• Overview
• MUC1 in Human Cancer: The Numbers
  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Esophagus Cancer
  • Gastric Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Acute Myeloid Leukemia (AML)
  • Multiple Myeloma
• MUC1 in Human Cancer: Overexpression
• Target for Carcinoma Stem-like Cell
• Target for Leukemia Stem Cell
• MUC1 Resides in an Immune Privileged Site
• Intellectual Property

Programs

• The Pipeline
• Targeting the Cytoplasmic Domain
• Targeting the Extracellular Domain
• Biomarker Program

News and Publications

• News
• Publications
  • Complete Listing
  • Role of MUC1-C in Signal Transduction
  • Role of MUC1-C in Epigenetic Regulation
  • Role of MUC1-C in Immune Evasion
  • MUC1 Vaccine
  • MUC1-C in Stem-like Cells
  • MUC1-C inhibitor formulated in nanoparticles
  • MUC1-C is synergistic with chemotherapeutic and targeted drugs
  • MUC1-C is a druggable target

sitemap.xml
File Size:	7 kb
File Type:	xml

Download File

---